We're excited to announce that John Porter, PhD, former program director of the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) will take on the role of Chief Executive Officer for Parent Project Muscular Dystrophy.
As program director at the NIH/NINDS, Dr. Porter was responsible for managing a portfolio of research grants across neuromuscular disorders and served as Executive Secretary of the interagency Muscular Dystrophy Coordinating Committee. Prior to that, he served as Professor of Neurology at Case Western Reserve University, where he was supported by the NIH and advocacy groups for research on muscle biology in health and disease, including muscle group responses to Duchenne.
“PPMD is beyond thrilled to have John Porter joining our team. For years now, John has been an ally of the Duchenne community, making Duchenne research a priority at NINDS. He helped put this disease on the federal radar and as a result has helped facilitate research from minimal investment from the federal government, into tens of millions of dollars dedicated to muscular dystrophy research. When I heard John was retiring from NIH, I thought ‘what a dream it would be to have someone with John’s talents at PPMD, dedicated to this community.’ Today is proof that dreams do come true!"
-- PPMD’s Founding President Pat Furlong
As CEO, Dr. Porter will help PPMD continue to integrate programs to maximize impact, building upon current programs and exploring opportunities to expand the research pipeline, with the goal of accelerating progress and approvals. Dr. Porter joins PPMD’s Founding President, Pat Furlong and Chief Operating Officer, Kimberly Galberaith, in leading the organization.
“After conducting research in my own laboratory in academia for over 20 years, and then facilitating the funding of neuromuscular disease research by the NINDS for the next 10 years, PPMD offered me this unparalleled opportunity to synthesize that experience and bring it directly to bear on the challenges of better quality of life and novel treatments for people with Duchenne. I’m thrilled to join such a strong and vibrant team at PPMD, and work with the broader community of dedicated scientists, physicians, patient advocates, and families, in a leave no-stone-unturned approach to end Duchenne.”
-- Dr. Porter